Publication:
EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells

dc.contributor.authorMutz, Cornelia N
dc.contributor.authorSchwentner, Raphaela
dc.contributor.authorAryee, Dave N T
dc.contributor.authorBouchard, Eric D J
dc.contributor.authorMejia, Edgard M
dc.contributor.authorHatch, Grant M
dc.contributor.authorKauer, Maximilian O
dc.contributor.authorKatschnig, Anna M
dc.contributor.authorBan, Jozef
dc.contributor.authorGarten, Antje
dc.contributor.authorAlonso, Javier
dc.contributor.authorBanerji, Versha
dc.contributor.authorKovar, Heinrich
dc.contributor.funderFWF Austrian Science Fund
dc.contributor.funderUnión Europea. Comisión Europea. 7 Programa Marco
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderRed Temática de Investigación Cooperativa en Cáncer (RTICC) (España)
dc.date.accessioned2020-04-17T16:02:04Z
dc.date.available2020-04-17T16:02:04Z
dc.date.issued2017-04-11
dc.description.abstractEwing sarcoma (EwS) is the second most common bone cancer in children and adolescents with a high metastatic potential. EwS development is driven by a specific chromosomal translocation resulting in the generation of a chimeric EWS-ETS transcription factor, most frequently EWS-FLI1.Nicotinamide adenine dinucleotide (NAD) is a key metabolite of energy metabolism involved in cellular redox reactions, DNA repair, and in the maintenance of genomic stability. This study describes targeting nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of NAD synthesis, by FK866 in EwS cells. Here we report that blocking NAMPT leads to exhaustive NAD depletion in EwS cells, followed by a metabolic collapse and cell death. Using conditional EWS-FLI1 knockdown by doxycycline-inducible shRNA revealed that EWS-FLI1 depletion significantly reduces the sensitivity of EwS cells to NAMPT inhibition. Consistent with this finding, a comparison of 7 EwS cell lines of different genotypes with 5 Non-EwS cell lines and mesenchymal stem cells revealed significantly higher FK866 sensitivity of EWS-ETS positive EwS cells, with IC50 values mostly below 1nM.Taken together, our data reveal evidence of an important role of the NAMPT-mediated NAD salvage pathway in the energy homeostasis of EwS cells and suggest NAMPT inhibition as a potential new treatment approach for Ewing sarcoma.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipAustrian Science Fund (FWF), grant I1225-B19; European Union's FP7 project ASSET (grant agreement No. 259348); Research Manitoba and CancerCare Manitoba Foundation. Heart and Stroke Foundation of Canada (G-14-0005708). E.M.M. is the recipient of a Research Manitoba Graduate Studentship. G.M.H. is the Canada Research Chair in Molecular Cardiolipin Metabolism. J.A. is supported by Asociación Pablo Ugarte and Miguelañez S.A, ASION-La Hucha de Tomás, Fundación La Sonrisa de Alex and Instituto de Salud Carlos III (PI12/00816 and Spanish Cancer Network RTICC RD12/0036/0027).es_ES
dc.format.number15es_ES
dc.format.page24679-24693es_ES
dc.format.volume8es_ES
dc.identifier.citationOncotarget. 2017 Apr 11;8(15):24679-24693.es_ES
dc.identifier.doi10.18632/oncotarget.14976es_ES
dc.identifier.e-issn1949-2553es_ES
dc.identifier.issn1949-2553es_ES
dc.identifier.journalOncotargetes_ES
dc.identifier.pubmedID28160567es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9613
dc.language.isoenges_ES
dc.publisherImpact Journals
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/ I1225-B19es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/G-14-0005708es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI12/00816es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/259348es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD12/0036/0027es_ES
dc.relation.publisherversionhttps://doi.org/10.18632/oncotarget.14976es_ES
dc.repisalud.centroISCIII::Instituto de Investigación de Enfermedades Rarases_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectEWS-FLI1es_ES
dc.subjectEwing sarcomaes_ES
dc.subjectFK866es_ES
dc.subjectNADes_ES
dc.subjectNAMPTes_ES
dc.subject.meshAcrylamideses_ES
dc.subject.meshBone Neoplasmses_ES
dc.subject.meshCell Line, Tumores_ES
dc.subject.meshCytokineses_ES
dc.subject.meshDrug Resistance, Neoplasmes_ES
dc.subject.meshEnzyme Inhibitorses_ES
dc.subject.meshHeLa Cellses_ES
dc.subject.meshHumanses_ES
dc.subject.meshNADes_ES
dc.subject.meshNicotinamide Phosphoribosyltransferasees_ES
dc.subject.meshOncogene Proteins, Fusiones_ES
dc.subject.meshPiperidineses_ES
dc.subject.meshProto-Oncogene Protein c-fli-1es_ES
dc.subject.meshRNA-Binding Protein EWSes_ES
dc.subject.meshSarcoma, Ewinges_ES
dc.titleEWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cellses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication7416f724-f758-4723-8e95-ca2ff70ee53c
relation.isAuthorOfPublication.latestForDiscovery7416f724-f758-4723-8e95-ca2ff70ee53c
relation.isFunderOfPublication9b196840-911f-4f05-8a58-08e77d45c35f
relation.isFunderOfPublication453a1d63-c349-4a0e-b0f2-f4edba065c75
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication3fb2c806-a1bc-429e-99df-4c2e50f8a129
relation.isFunderOfPublication.latestForDiscovery9b196840-911f-4f05-8a58-08e77d45c35f
relation.isPublisherOfPublication308f485e-2d81-409c-85ad-82f4b1afd9a1
relation.isPublisherOfPublication.latestForDiscovery308f485e-2d81-409c-85ad-82f4b1afd9a1

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
EWSFLI1ConfersExquisite_2017.pdf
Size:
3.73 MB
Format:
Adobe Portable Document Format
Description: